Health Canada's Clinical Trials Database is a listing of information about phase I, II and III clinical trials in patients. The database is managed by Health Canada and provides a source of information about Canadian clinical trials involving human pharmaceutical and biological drugs. Additional information on Health Canada’s CTD is available at: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/health-canada-clinical-trials-database/frequently-asked-questions.html

Health Canada's Clinical Trials Database is a listing of information about phase I, II and III clinical trials in patients. The database is managed by Health Canada and provides a source of information about Canadian clinical trials involving human pharmaceutical and biological drugs. Additional information on Health Canada’s CTD is available at: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/health-canada-clinical-trials-database/frequently-asked-questions.html

Health Canada has authorized certain clinical trials in patients in Canada. Our public Clinical Trials Database is a public listing of specific information relating to these trials. Additional publicly accessible registries that further support finding suitable trials are: ClinicalTrials.gov and Current Controlled Trials International Standard Randomized Controlled Trials Number Register.

Health Canada, through its Clinical Trials Database, is providing to the public a listing of specific information relating to phase I, II and III clinical trials in patients. The database is managed by Health Canada and provides a source of information about Canadian clinical trials involving human pharmaceutical and biological drugs.

Health Canada has authorized certain clinical trials in patients in Canada. Our public Clinical Trials Database is a public listing of specific information relating to these trials. Additional publicly accessible registries that further support finding suitable trials are: ClinicalTrials.gov and Current Controlled Trials International Standard Randomized Controlled Trials Number Register.

Objectives: This study examines the characteristics of studies that Health Canada uses to grant full marketing authorization for products given a conditional approval between January 1, 1998 and June 30, 2017.

Design: Cohort study.

Data sources: Journal articles listing drugs that fulfilled their conditions and received full marketing authorization, Notice of Compliance database, Notice of Compliance with conditions web site, Qualifying Notices listing required confirmatory studies, clinicaltrials.gov, PubMed, Embase, companies making products being analyzed, journal articles resulting from confirmatory studies.

Interventions: None

Primary and secondary outcome measures: Characteristics of studies - study design (randomized controlled trials, observational), primary outcome used (clinical, surrogate), blinding, number of patients in studies, patient median age, number of men and women.

Results: Eleven companies confirmed 36 publications for 19 products (21 indications). Twenty-nine out of the 36 studies were randomized controlled trials (RCTs) but only 10 stated if they were blinded. Twenty used surrogate outcomes. The median age of patients was 56 (interquartile range (IQR) 44, 61). The median number of men per study/trial was 184 (IQR 58, 514) versus women - 141 (IQR 46, 263).

Conclusions: Postmarket studies required by Health Canada had more rigorous methodology than those required by either the Food and Drug Administration or the European Medicines Agency. There were still deficiencies in these studies. The absence of blinding in the majority of RCTs may introduce bias in their results. The use of surrogate outcomes especially in oncology trials means that improvements in survival are not available. The relatively young age of patients, even for products for cancer, means that predicting how the elderly will respond is often unknown. The almost universal finding that men outnumbered number women may make it hard to differentiate responses by sex. These results raise potential concerns about the quality of evidence that Health Canada accepts.

Ce jeu de données contient les stratégies de recherche pour les banques de données suivantes : MEDLINE (OVID), EMBASE (OVID), EBM Reviews (OVID), PsycInfo (OVID), CINAHL Complete (EBSCO), Clinicaltrials.gov, ICTRP, ISRCTN, Health Canada Clinical Trials Database, NIHR and Google Scholar. Les concepts recherchés sont "methamphetamine", "psychosocial intervention" and "randomized clinical trials"

Study design We conducted a cross-sectional study to quantify the number and describe the characteristics of prescription drugs on the Canadian market as of August 23, 2022 with a patient support program defined as services (including but not limited to financial assistance) offered to patients prescribed a specific drug and initiated and funded by the manufacturer. We then conducted a structured content analysis of web-based sources to understand the types and range of supports provided to patients through these programs. We chose to rely exclusively on publicly available data sources to both identify and describe manufacturer-sponsored patient support programs as these are sources currently available to patients when making program enrolment decisions and policymakers seeking to understand the extent and impact of this model of care. Sampling frame Because the European Medicines Association defines a patient support program as services for a specific drug offered by the company holding the marketing authorization, we first sought to identify all drug companies with currently marketed, prescription products in Canada. Between June 27, 2022 and August 23, 2022, two investigators independently extracted the names of all member companies listed on the websites of the three main trade associations for the Canadian pharmaceutical industry (Innovative Medicines Canada, representing the research-based pharmaceutical industry; BIOTECanada, representing the biotechnology industry; and the Canadian Generic Pharmaceutical Association, representing generic drug manufacturers). Because trade association membership is voluntary, we supplemented this list with non-member drug manufacturers identified in previous research. Using the Health Canada Drug Product Database,two investigators independently screened the list of companies and included those with marketed, prescription products and excluded companies that were not drug manufacturers (e.g., law firms) or without currently marketed prescription drugs (e.g., products under development). Discrepancies were resolved through discussion or adjudication by a third author. Sample and variables Using the Health Canada Drug Product Database, one investigator searched each identified drug manufacturer and extracted the product and active ingredient name(s) for all marketed, prescription drugs. We counted a single “drug” as all dosages, formulations, or routes of administration with the same active ingredients and manufacturer since industry patient support programs are brand-specific and do not typically differentiate among these factors. We selected variables that reflect known characteristics of drugs that may be associated with having a patient support program, and for which data were publicly available. One investigator also extracted Schedule D (biologic) status, route(s) of administration, and Level 1 Anatomical Therapeutic Chemical (ATC) code from the Drug Product Database and Product Monograph and identified whether the drug had Orphan Drug Status using the searchable United States database. On the basis of type of Health Canada regulatory review (i.e. innovator or subsequent entry), clinical expertise, and knowledge about the manufacturer, two investigators independently identified the brand status of each drug as brand (i.e. “innovator” products first to market); branded generic (i.e. “subsequent entry” products which are bioequivalent or biosimilar to an existing product on the market, but given a proprietary name); or generic (i.e. “subsequent entry” products which are bioequivalent to an existing product on the market). We classified biosimilars as branded generics. We resolved discrepancies through discussion, and/or adjudication by a third author. Identifying patient support programs and their characteristics Our primary outcome was whether a sampled drug had an associated manufacturer-sponsored patient support program. We defined a patient support program as any combination of services or resources related to medication access, administration, adherence, education, storage, or disposal for patients prescribed a specific product and initiated, sponsored and/or operated by the company holding the product’s marketing authorization. We distinguished patient support programs from “patient assistance programs,” excluding programs that exclusively provided financial assistance (e.g., coupons, co-pay coverage, etc.); expanded or compassionate access programs; risk management programs outlined in the Product Monograph (initiated by the regulator rather than the manufacturer); and programs delivered solely for a clinical study. Two investigators independently performed structured searches on Google (“[company name] AND patient support program AND Canada” and “[drug brand name] AND patient support program AND Canada”) to identify industry sponsored patient support programs in Canada and resolving discrepancies through discussion. Using Zotero, a reference management...

BackgroundA better understanding of the current characteristics of clinical trials on thyroid cancer (TC) is important to improve trial designs and identify neglected areas of research. However, there is a lack of a thorough understanding of the clinical studies on TC. Therefore, this study aimed to present a comprehensive overview of clinical trials on TC based on the ClinicalTrials.gov database and evaluate their publication status.MethodsWe searched for TC-related clinical studies registered in the ClinicalTrials.gov database before December 2018 by using the keyword “thyroid cancer” and assessed the characteristics of the included trials. We searched the publication status of primary completed studies in PubMed and Google Scholar.ResultsA total of 450 studies were identified for analysis, including 333 (74.0%) interventional studies and 117 (26.0%) observational studies. Interventional studies about TC were commonly non-randomized (67.6%), single-arm (55.6%), single-center (76.3%), and early-phase (60.0%) trials. The major category for which studies were performed was for target drug-related therapy (53.6%). In addition, 57.0% of the primary completed interventional studies were published. The published studies were more commonly primary completed studies after 2010 and used randomization and were less commonly designed as single-arm studies and were conducted in the USA/Canada, compared to non-published studies (P < 0.05 for all). The median time from primary completion to publication was 46.5 months, and the time decreased to 36.5 months after 2010. Studies conducted in the USA/Canada [odds ratio (OR) = 9.43, P = 0.020] and multi-center studies (OR = 6.55, P = 0.021) significantly increased the potential of publication in high-impact journals.ConclusionsHigh-quality, randomized phase 3 trials regarding TC are still insufficient. Therefore, more efforts are needed to improve the treatment of poor prognostic TC and timely publication.

Snapshot img

Contract Research Organization (CRO) Market Size 2025-2029

The contract research organization (cro) market size is forecast to increase by USD 85.3 billion, at a CAGR of 14.6% between 2024 and 2029.

The market experiences significant growth, driven primarily by the burgeoning biopharmaceutical industry and the increasing number of clinical trials. The biopharmaceutical sector's expansion fuels the demand for CROs, as these organizations provide essential services in conducting clinical trials, enabling the development and approval of new drugs. However, the CRO industry encounters challenges, most notably intellectual property issues. As companies collaborate with CROs to outsource clinical trials, the protection and management of intellectual property become crucial. Ensuring the confidentiality and security of data, as well as addressing potential patent disputes, are significant hurdles that CROs must navigate to maintain trust and credibility with their clients. Companies seeking to capitalize on market opportunities and navigate challenges effectively must focus on robust intellectual property management strategies and innovative solutions to address these obstacles.

What will be the Size of the Contract Research Organization (CRO) Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free SampleThe market continues to evolve, driven by the dynamic nature of pharmaceutical and medical device development. CROs play a crucial role in optimizing cost structures, ensuring patient recruitment, and reducing time to market for various sectors. They offer seamless integration of services, including phase II trials, clinical trial databases, trial success rate enhancement, and phase III trials. CROs provide specialized expertise in medical device development, clinical operations, safety monitoring, and study design. They offer regulatory approvals assistance, market authorization, and post-marketing surveillance. Data management, data analysis, and statistical analysis are integral to their offerings. Biopharmaceutical companies increasingly rely on CROs for pharmacokinetic (PK) studies, biomarker analysis, and clinical trial software. Informed consent, protocol development, clinical trial management, and regulatory affairs are also key areas of focus. CROs ensure data integrity through clinical endpoint assessment, phase I trials, and audit trails. They offer investigator training, site management, and adverse event reporting. CRO services extend to therapeutic areas, disease models, and clinical trial management. Quality assurance and safety monitoring are essential components of CRO offerings, ensuring regulatory compliance and trial success. CROs also provide bioequivalence studies, clinical trial database management, and phase IV trials support. The ongoing unfolding of market activities reveals evolving patterns in CRO services, reflecting the continuous nature of drug development and medical device innovation.

How is this Contract Research Organization (CRO) Industry segmented?

The contract research organization (cro) industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments. ApplicationClinical researchEarly phase developmentLaboratoryRegulatory consultingEnd-userPharmaceutical and biopharmaceutical companiesMedical device companiesAcademic institutesGeographyNorth AmericaUSCanadaEuropeFranceGermanyUKMiddle East and AfricaUAEAPACChinaIndiaJapanSouth AmericaBrazilRest of World (ROW).

By Application Insights

The clinical research segment is estimated to witness significant growth during the forecast period.Clinical research organizations (CROs) provide essential services to the pharmaceutical industry, overseeing various aspects of drug development and medical device innovation. CROs facilitate pharmacokinetic (pk) studies, biomarker analysis, and clinical trial software implementation to optimize clinical trials. Informed consent processes are meticulously managed to ensure ethical conduct. CROs play a critical role in the drug development lifecycle, from study design and regulatory approvals to data management and analysis, safety monitoring, and post-marketing surveillance. Their expertise in clinical trial management expedites the time to market, enhancing efficiency and compliance. Bioequivalence studies, data integrity, and cost optimization are crucial elements of CRO services. Patient recruitment is streamlined through specialized expertise and clinical operations. Medical device development and clinical endpoint research are also within their purview. CROs collaborate with research centers for tissue-based clinical research, sp

Comprehensive dataset of 121 Medical schools in Canada as of June, 2025. Includes verified contact information (email, phone), geocoded addresses, customer ratings, reviews, business categories, and operational details. Perfect for market research, lead generation, competitive analysis, and business intelligence. Download a complimentary sample to evaluate data quality and completeness.

One in five Canadians experiences chronic pain, at a cost of $40.3 billion in 2019. Despite this significant burden, there are few effective treatments for pain. This gap has been recognized by Health Canada, which has put forth the Action Plan for Pain in Canada. Advancing our understanding of pain mechanisms and clinical trials to identify novel therapeutics are essential to address this treatment gap. However, it remains unknown whether the recommendations of the Action Plan have increased research investments. We investigate research investments in pain by the Canadian Institutes of Health Research (CIHR) based on publicly available data. We performed a systematic database search focused on operating funds from competitions between 2008 and 2023 and tabulated pain funding as a proportion of total CIHR operational funds granted each year. Next, we examined the proportion of pain funding across CIHR institutes aggregated across funding years. We identified 20,126 operational grants, of which 459 were pain focused. The highest level of pain funding was 3.32% in 2019, and the average (SD) was 2.13% (0.70%). Funding was stagnant from 2008 to 2023 (R2 = 0.10, P = 0.23). The Institute of Musculoskeletal Health and Arthritis allocated the largest proportion of funding to pain research (11.40%). Eight of the 13 institutes allocated less than 1% of their operating funds to pain research. In sum, CIHR pain research funding does not match the socioeconomic burden posed by pain. We propose three action items to improve pain research funding and to ultimately relieve the burden of pain in Canada.

Comprehensive dataset of 1 Drug testing services in Yukon, Canada as of June, 2025. Includes verified contact information (email, phone), geocoded addresses, customer ratings, reviews, business categories, and operational details. Perfect for market research, lead generation, competitive analysis, and business intelligence. Download a complimentary sample to evaluate data quality and completeness.

BackgroundUrinary retention (UR) is a clinical condition where patients cannot fully empty their bladder. Although numerous drugs are associated with UR, comprehensive and reliable studies identifying drugs that induce UR are scarce.MethodsThis study leveraged data from the FDA Adverse Event Reporting System (FAERS) and the Canadian Vigilance Adverse Reaction (CVAR) database to explore adverse events (AEs) related to UR from 2004 to Q1 2024. The top 50 drugs were analyzed for annual reporting trends using linear regression. Disproportionality analysis using the reporting odds ratio (ROR) method, with P-values adjusted via Bonferroni correction, identified significant signals, which were then validated against drug labels and re-evaluated using the CVAR database. Time-to-onset analysis was also performed.ResultsFrom 2004 to Q1 2024, FAERS recorded 17,785,793 AEs, with 16,183 (0.09%) identified as UR cases. The median age among these cases was 65 years, with males comprising 53.4%. There were significant annual increases in UR reports associated with antineoplastic agents (0.19% per year) and antidiabetic drugs (0.09% per year), while reports linked to bronchodilators decreased (−0.53% per year). Disproportionality analysis revealed significant signals for 34 drugs (68%), with the highest RORs observed in Fesoterodine, Mirabegron, and Solifenacin. Initial signal detection identified potential new UR signals for Abiraterone, Valacyclovir, Fluoxetine, Empagliflozin, Clopidogrel, and Amlodipine, with CVAR confirming signals for Abiraterone, Fluoxetine, and Empagliflozin. The median time to onset of UR was 29 days, with over half of the cases occurring within 30 days of initiating medication.ConclusionThe study identifies a rising trend in drug-related UR reports over the past 2 decades. The validation of new signals for Abiraterone, Fluoxetine, and Empagliflozin underscores the critical need for continuous drug safety monitoring and targeted research to better understand the mechanisms behind drug-induced UR.

Comprehensive dataset of 20 Drug testing services in Quebec, Canada as of June, 2025. Includes verified contact information (email, phone), geocoded addresses, customer ratings, reviews, business categories, and operational details. Perfect for market research, lead generation, competitive analysis, and business intelligence. Download a complimentary sample to evaluate data quality and completeness.

Comprehensive dataset of 54 Drug testing services in Ontario, Canada as of June, 2025. Includes verified contact information (email, phone), geocoded addresses, customer ratings, reviews, business categories, and operational details. Perfect for market research, lead generation, competitive analysis, and business intelligence. Download a complimentary sample to evaluate data quality and completeness.

Dataset Description: This dataset contains materials from the Smart Discharges for Mom & Baby parent study within the Smart Discharges program of research. Materials include the parent study ethics protocol and associated documents. See the Metadata section below for links to related publications and datasets. Background: In low-income country settings, the first six weeks after birth remain a critical period of vulnerability for both mother and newborn. Despite recommendations for routine post-discharge follow-up, few mothers and newborns receive guideline recommended care during this period. Prediction modelling of post-delivery outcomes has the potential to improve outcomes for both mother and newborn by identifying high-risk dyads, improving risk communication, and facilitating a patient-centered approach to postnatal care. Methods: This is a mixed-methods study to explore and map the current postnatal discharge processes in Uganda.We will conduct an observational cohort study (Phase I) to develop and internally validate our risk score and aim to recruit 7,000 mother and newborn dyads from Jinja Regional Referral Hospital and Mbarara Regional Referral Hospital. We will also engage with patients, families, and health workers through patient journey mapping and focus group discussions (Phases II-IV) to identify barriers and facilitators to inform the development of an evidence- and risk-based bundle of interventions to improve postnatal care (PNC) for dyads. The primary outcome is maternal and/or neonatal death or need for re-admission within six weeks of birth. Secondary outcomes include: 1. Post-natal care visits during the 6-week post-discharge period 2. Post-discharge health seeking practices for mothers/newborns during the 6-week post-discharge period 3. Causes of readmission/mortality among those who experience such outcomes, based on verbal autopsies and admission symptom/diagnosis questionnaires. Data Collection Methods: All data will be collected at the point of care using encrypted study tablets. These data will be uploaded to a Research Electronic Data Capture (REDCap) database hosted at the BC Children’s Hospital Research Institute (Vancouver, Canada). At admission, trained study nurses will systematically collect data on clinical, social and demographic variables. Following discharge, field officers will contact mothers at 6-weeks post-discharge, to determine vital status, post-discharge health-seeking, and readmission details. Verbal autopsies were conducted for participants who had died following discharge. Direct observation and interviews will be conducted on a sub-set of participants to collect process outcomes and barriers and facilitators to the patient's journey. FGDs will be digitally recorded, transcribed verbatim in the language spoken during the recording and analyzed for emerging themes. Ethics Declaration: Ethics approvals have been obtained from the Makerere University School of Public Health (MakSPH) Institutional Review Board (SPH-2021-177), the Uganda National Council of Science and Technology (UNCST) in Uganda (HS2174ES) and the University of British Columbia in Canada (H21-03709). This study has been registered at clinicaltrials.gov (NCT05730387). Associated datasets: Pending publication NOTE for restricted files: If you are not yet a CoLab member, please complete our membership application survey to gain access to restricted files within 2 business days. Some files may remain restricted to CoLab members. These files are deemed more sensitive by the file owner and are meant to be shared on a case-by-case basis. Please contact the CoLab coordinator on this page under "collaborate with the pediatric sepsis colab."

What is covered in the report about the “Canada Anesthesia and Respiratory Devices Market”? GlobalData’s “Canada Anesthesia and Respiratory Devices Market Outlook to 2021” report is a comprehensive databook report, covering key market data on the Canada Anesthesia and Respiratory Devices market. The databook report provides value (USD) and volume (units) within market categories – Airway and Anesthesia Devices, Anesthesia Machines, Pain Management Devices, Regional Anesthesia Disposables, Respiratory Devices, Respiratory Disposables, Respiratory Measurement Devices and Sleep Apnea Diagnostic Systems. The Canada Anesthesia and Respiratory Devices Market report provides key information and data on • Annualized market revenues (USD) and volume (units) data for each of the market segments. Data is provided from 2007 to 2014 and forecast to 2021. • 2014 company share and distribution share data for Anesthesia and Respiratory Devices market. • Global corporate-level profiles of key companies operating within the Canada Anesthesia and Respiratory Devices Market. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is also available in the report. Canada Anesthesia and Respiratory Devices is segmented as follows: • Airway and Anesthesia Devices • Anesthesia Machines • Pain Management Devices • Regional Anesthesia Disposables • Respiratory Devices • Respiratory Disposables • Respiratory Measurement Devices • Sleep Apnea Diagnostic Systems Key Reasons to Purchase The Canada Anesthesia and Respiratory Devices Market report helps you to develop • Business strategies by identifying the key market segments poised for strong growth in the future. • Market-entry and market expansion strategies. • Design competition strategies by identifying who-stands-where in the market. • Develop investment strategies by identifying the key market segments expected to register strong growth in the near future. • Understand the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize. Key companies covered in the “Canada Anesthesia and Respiratory Devices Market Outlook to 2021” report • Medtronic plc • Philips Respironics, Inc. • ResMed Inc. • Smiths Medical • GE Healthcare • Teleflex Incorporated • Draegerwerk AG & Co. KGaA The GlobalData Differentiation Extensive interviews are conducted with industry experts to validate the market size, company share and distribution share data and analysis. The data and analysis within this report are driven by GlobalData Medical Equipment (GDME) databases. GlobalData Medical Equipment database gives you the key information required to drive sales, investment and deal-making activity in your business. It includes the following: • 15,000+ data tables showing market size across more than 780 medical equipment segments and 15 countries, from 2007 and forecast to 2021 • 6,000+ primary interviews, conducted annually to ensure data and report quality • Approximately 4,000+ medical equipment conference reports, industry-leading analysis reports covering growing sectors, market trends, investment opportunities and competitive landscape • 600+ medical equipment trends and issues, and investment and M&A trends • 55,000+ medical equipment company profiles • 4,100+ company profiles of medical equipment manufacturers in China and India • 2,000+ company profiles of medical equipment manufacturers in Japan • 825+ companies’ revenue splits and market shares • 1,750+ quarterly and annual medical equipment company financials • 700+ medical equipment company SWOTs • 18,000+ pipeline product profiles • 24,800+ marketed product profiles • 31,600+ clinical trials • 25,000+ trial investigators • 20,600+ product patents • 3,700+ reports on companies with products in development • 21,500+ reports on deals in the medical equipment industry • 1,300+ surgical and diagnostic procedures by therapy area • 50+ key healthcare indicators by country For more information or to receive a free demonstration of the service, please visit: http://globaldata.com/medical/Home.aspx Custom Requirements Contact us to discuss the areas of your business where you need external input, and we will work with you to identify the strongest way forward to meet your needs. Read More

The database contains data about the biomedical publications on Ebola in 2014.The volumes of publications and the classifications were determined by using the PubMed search engine. The data are ordered according to different criteria. Columns/row headings and embedded comments describe the contents of the columns/rows. Columns A-K of sheets ‘Clinical Trial term’, ‘Canada’, ‘China’, ‘France’, ‘Germany’, ‘Guinea’, ‘Liberia’, ‘Sierra Leone’, ‘UK’, ‘USA’ were from csv files downloaded from PubMed searches.Further information about the methodology and the data is contained in the associated article. All data and figures mentioned in the associated article and this figshare entry are linked to a sheet of this database. Figure 3Numbers of citations with ‘ebola’ or ‘ebolavirus’ in title from 1995 to 2014. Figure 4Numbers of citations (abstract available) with ‘ebola’ or ‘ebolavirus’ in title from 1995 to 2014. Figure 5Proportions of citations (‘ebola’ or ‘ebolavirus’ in title) with abstract available from 2005 to 2014. Figure 15Proportions of citations (‘ebola’ or ‘ebolavirus’ in title) with abstract available with the indicated search terms in the title/abstract. Year 2014. Figure 16Proportions of citations (‘ebola’ or ‘ebolavirus’ in title) with the search term ‘clinical trial’ in the title/abstract. The number of publications about original clinical trial studies is also indicated. Year 2014. Figure 17Numbers of citations (‘ebola’ or ‘ebolavirus’ in title) per month. Year 2014. Figure 18Numbers of citations (‘ebola’ or ‘ebolavirus’ in title) with abstract available per month. Year 2014. Figure 19Subjective classification for ‘current outbreak’ focus of 2014 citations (‘ebola’ or ‘ebolavirus’ in title). Remaining citations were assigned to one (and only one) of the indicated discipline/area categories. Year 2014. Figure 20Subjective classification for current outbreak focus or, alternatively, for the indicated discipline/area categories of 2014 citations (‘ebola’ or ‘ebolavirus’ in title) per month. Citations were assigned to one (and only one) category, similarly to Figure 19. Year 2014. Figure 21Numbers of citations (‘ebola’ or ‘ebolavirus’ in title) during 2014 with search term ‘outbreak’ in title/abstract. Figure 22Numbers of citations (‘ebola’ or ‘ebolavirus’ in title) during 2014 with search term ‘Africa’ in title/abstract. Figure 23Numbers of citations (‘ebola’ or ‘ebolavirus’ in title) during 2014 with search terms ‘vaccine’ or ‘vaccines’ in title/abstract. Figure 24Numbers of total biomedical citations of the 20 countries with most total biomedical publications. Year 2014. Figure 25Numbers of citations (‘ebola’ or ‘ebolavirus’ in title) of the 20 countries with most total biomedical publications. Year 2014. Figure 28Numbers of total citations with abstract available of the 20 countries with most total biomedical publications. Year 2014. Figure 29Numbers of citations (‘ebola’ or ‘ebolavirus’ in title) with abstract available of the 20 countries with most total biomedical publications. Year 2014. Figure 31Numbers of citations (‘ebola’ or ‘ebolavirus’ in title) of the six countries with most Ebola-related publications. Citations (‘ebola’ or ‘ebolavirus’ in title) with abstract available are also shown. Year 2014. Figure 32‘Manual’ control test of the method for country affiliation attribution.Numbers of citations (‘ebola’ or ‘ebolavirus’ in title) with abstract available of the six countries with most Ebola-related publications. The numbers of publications automatically retrieved or with real ‘any author’, ‘first author’ or ‘last author’ with the proper country affiliation are indicated. 100% of the citations had at least one author (‘any author’) with the proper country affiliation, thus indicating accuracy of the method. Year 2014. Figure 33Subjective classification for article type of citations (‘ebola’ or ‘ebolavirus’ in title) with abstract available of the United States and Canada, the two countries with most Ebola-related publications with abstract available. Year 2014. Figure 34Subjective classification for discipline/area of citations (‘ebola’ or ‘ebolavirus’ in title) with abstract available of the United States and Canada, the two countries with most Ebola-related publications with abstract available. Citations were assigned only to the more relevant category, except citations related to specific aspects of the 2014 outbreak that were assigned optionally and in addition to the other categories. Year 2014. Figure 35 Numbers of total biomedical citations and citations (‘ebola’ or ‘ebolavirus’ in title) of Sierra Leone, Liberia and Guinea, the three countries with most Ebola cases. Year 2014.

Snapshot img

Cancer Registry Software Market Size 2025-2029

The cancer registry software market size is forecast to increase by USD 121.9 million, at a CAGR of 14% between 2024 and 2029.

The market is witnessing significant growth, driven by the increasing prevalence of cancer cases and the rising demand for accurate and comprehensive data for clinical research in oncology. The growing number of cancer diagnoses worldwide necessitates advanced solutions for managing and analyzing patient data, fueling market expansion. Furthermore, the importance of data privacy and security in the healthcare sector poses a challenge for market participants. Ensuring the confidentiality and protection of sensitive patient information is crucial to maintain trust and regulatory compliance.
Companies in this market must navigate these challenges while continuing to innovate and deliver solutions that address the evolving needs of healthcare providers and researchers. By focusing on data security and privacy, as well as integrating advanced analytics capabilities, market participants can capitalize on the opportunities presented by the growing demand for cancer registry software.

What will be the Size of the Cancer Registry Software Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free Sample

The market continues to evolve, driven by advancements in technology and the increasing demand for efficient and accurate cancer data management. Cloud computing plays a significant role in the market's dynamics, enabling remote access to data and reducing the need for on-premise infrastructure. Technical support, audit trails, and cancer surveillance are integral components of these solutions, ensuring data security and regulatory compliance. Data warehousing and business intelligence capabilities enable data cleansing, data validation, and data analysis, leading to improved data quality and clinical insights. User experience and customizable reports cater to diverse user needs, while machine learning and artificial intelligence facilitate predictive modeling and statistical analysis.

Healthcare regulations mandate stringent data governance and access control, making data security a top priority. Case management and healthcare IT integration streamline workflows and facilitate data exchange between various stakeholders. Database management and reporting features provide real-time data visualization and decision support, enhancing operational efficiency. Data migration and software updates ensure seamless integration with existing systems, while data validation and data entry tools maintain data accuracy. Tumor registry solutions enable comprehensive cancer surveillance and population health management, contributing to public health initiatives. The market's continuous dynamism reflects the ongoing integration of various technologies and the evolving needs of healthcare providers and regulatory bodies.

How is this Cancer Registry Software Industry segmented?

The cancer registry software industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

End-user

  Government and third party
  Pharma biotech and medical device companies
  Hospitals and medical practice
  Private payers
  Research institutes


Type

  Stand-alone software
  Integrated software


Deployment

  On-premises
  Cloud-based


Geography

  North America

    US
    Canada
    Mexico


  Europe

    France
    Germany
    Italy
    Spain
    UK


  APAC

    China
    Japan


  Rest of World (ROW)

By End-user Insights

The government and third party segment is estimated to witness significant growth during the forecast period.

Cancer registry software plays a vital role in assisting government and third-party agencies in managing and analyzing data related to cancer cases. These solutions enable the collection, storage, and processing of patient data, clinical information, and statistical analysis. The integration of business intelligence and data warehousing facilitates data mining, trend analysis, and pattern recognition, which is essential for public health planning and resource allocation. Machine learning and artificial intelligence technologies enhance the capabilities of cancer registry software by automating data entry, improving data accuracy, and enabling predictive modeling. User-friendly interfaces, customizable reports, and decision support systems cater to the needs of healthcare IT professionals, medical informatics specialists, and other stakeholders.

Database management, workflow management, and access control ensure data security and privacy, while data governance and da